There are many factors that influence relapse in schizophrenia, and it is certain that patients with schizophrenia who discontinue medication have a much greater risk of relapse than those who remain on medication, but those who remain on medication are at increased risk for side effects, including delayed dyskinesia (TD), extrapyramidal side effects (EPS), sedentary inability, sexual dysfunction, and other side effects. So is there a way to reduce relapse and at the same time reduce the risk of these side effects? Perhaps the lowest effective therapeutic dose of antipsychotic or a second-generation antipsychotic such as clozapine or risperidone could be considered. Atypical antipsychotics (e.g., clozapine) have the following advantages: better outcome for dissociative, positive, and negative symptoms, improved cognitive function, reduced risk of TD, minimal EPS, no elevated prolactin levels, reduced risk of suicide and reduced need for hospitalization, and lower total cost of treatment. Further studies on maintenance therapy should include comparative studies of the efficacy of oral or non-oral routes of clozapine, risperidone, or other new drugs versus low-dose conventional antipsychotics, and if the former is validated, it may be recommended as the route of maintenance therapy. Special attention should be paid to regular blood tests if clozapine is chosen as maintenance therapy to prevent the risk of granulocytopenia or deficiency. Adherence education is also particularly important in the prevention of relapse. Some patients refuse to take maintenance medication despite one or two relapses, so patient and family education is necessary to develop strategies early in the disease to improve adherence.